论文部分内容阅读
目的：探讨糖皮质激素联合小剂量利妥昔单抗治疗原发免疫性血小板减少症的临床应用效果。方法选取2012年1月至2014年1月江门市中心医院收治的120例原发免疫性血小板减少症患者为研究对象，随机分为对照组和干预组，每组60例。对照组在常规治疗基础上给予大剂量地塞米松冲击疗法，干预组在常规治疗基础上给予大剂量地塞米松和小剂量利妥昔单抗联合治疗方法。定期检测血小板数量，综合分析糖皮质激素联合小剂量利妥昔单治疗原发免疫性血小板减少症的临床应用效果。结果干预组的治疗总有效率明显偏高，为90.00%，差异有统计学意义（ p0.05）。干预组6周内血小板数量基本稳定的患者占70.00%，明显高于对照组（25.00%），差异有统计学意义（p<0.05）。结论糖皮质激素联合小剂量利妥昔单抗治疗原发免疫性血小板减少症的临床效果显著，值得进一步在临床上推广应用。“,”Objective to study the effect of gLucocorticoid in combination with smaLL dose of rituxan on primary immune thrombocytopenia. Methods One hundred and twenty cases of primary immune thrombocytopenia patients from January 2012 to January 2014 in Jiangmen centraL hospitaL were seLected as the research object and randomLy divided into controL group and inter-vention group with 60 cases in each group. the controL group were given high-dose dexamethasone therapy on the basis of conven-tionaL treatment,and intervention group received Large dose of dexamethasone and smaLL dose of rituxan joint treatment on the ba-sis of conventionaL treatment. PLateLet number were reguLarLy tested,and the cLinicaL effect of corticosteroids in combination with smaLL dose of rituximab on primary immune thrombocytopenia was comprehensiveLy anaLyzed. Results Compared with controL group,the totaL effective rate of intervention group was 90. 00%,and the difference was statisticaLLy significant(p0. 05). the patients with pLateLet num-ber 6 weeks basic stabiLity in intervention group accounted for 70. 00%,which was significantLy higher than that of the controL group(25. 00%),and the difference was statisticaLLy significant(p<0. 05). Conclusion the cLinicaL effect of gLucocorticoid in combination with smaLL dose of rituxan on primary immune thrombocytopenia is significant,and is worthy of further popuLariza-tion and appLication in cLinic.